Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4613 Correlation of serum cytokeratin 18, ferritin, cancer antigen 125, and beta-2 microglobulin with tumour grade and stage in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) remain challenging to diagnose, with limited reliable serum biomarkers available for early detection and prognostication.

Conference:

Presenting Author: Janas K

Authors: Janas K, Rosiek V, Kos-Kudła B,

Keywords: NEN, biomarker, analysis, diagnostic, pancreatic tumour,

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#4478 Association between serum biomarkers and liver tumour burden in advanced gastroenteropancreatic neuroendocrine tumours

Introduction: The association between serum biomarker levels and tumour burden is less studied in GEP-NET.

Conference:

Presenting Author: Jumai N

Authors: Jumai N, Chen L, Yusufu Y, Yan X, Liu M,

Keywords: Neuroendocrine tumour, tumour burden, prognosis, biomarker,

#4409 The value of NETest 2.0 in stratifying patients with suspected NEN for formal diagnostic evaluation – Real-world data

Introduction: An unmet need in NEN diagnosis is better risk stratification for individuals with suspected disease (based on symptoms or imaging), enabling efficient identification of those needing further evaluation and tissue diagnosis, thus speeding the process and reducing costs. NETest 2.0, a biomarker based on a 51-gene mRNA panel, was developed for diagnosing neuroendocrine neoplasia (NEN).

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, at-risk population, NEN,

#4313 Identification of gastroenteropancreatic neuroendocrine tumour patients with high liver tumour burden based on clinicopathological features

Introduction: Metastatic liver tumour burden (LTB) is a prognostic factor affecting the survival of gastroenteropancreatic neuroendocrine tumours (GEP-NETs), but evaluation of the LTB usually depends on radiologic and functional imaging.

Conference:

Presenting Author:

Authors: Jumai N, Chen L, Liu M, He Q, Zeng Z,

Keywords: liver tumour burden, prognosis, GEP-NET,